3 Drugs with the Most Severe Side Effects
Image Source
Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever.
The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news
La FDA elimina la Estrategia de Evaluación y Mitigación de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está eliminando la Estrategia de Evaluación y Mitigación de Riesgos (REMS por sus siglas en inglés) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que están aprobados como Avandia, Avandamet, Avandaryl y los genéricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news
La FDA elimina la Estrategia de Evaluaci ón y Mitigación de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está eliminando la Estrategia de Evaluación y Mitigación de Riesgos (REMS por sus siglas en inglés) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que están aprobados como Avandia, A vandamet, Avandaryl y los genéricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news
La FDA elimina la Estrategia de Evaluaci ó n y Mitigaci ó n de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administraci ó n de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en ingl é s) est á eliminando la Estrategia de Evaluaci ó n y Mitigaci ó n de Riesgos (REMS por sus siglas en ingl é s) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que est á n aprobados como Avandia, Avandamet, Avandaryl y los gen é ricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Follies, Part 2
Part 1 of this series appeared just over a year ago (in a different publication), and detailed a few of the agency's recent missteps. Prominently mentioned was the sad case of certain diabetes meds, including Actos, once touted as a safer alternative to Avandia. Avandia was taken off the market in 2011, but reappeared subject to severe limitations of use. These limitations were later removed—although current usage of the drug is small.
Oddly, Actos (FDA approved in July, 1999) was showing some problems (bladder cancer) as early as 2005, even though this information was not widely disseminated at the time. Some...
Source: Healthy Living - The Huffington Post - May 17, 2016 Category: Consumer Health News Source Type: news
FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 8, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program
[11-04-2011] The U.S. Food and Drug Administration (FDA) is reminding healthcare providers and patients about the need to enroll in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011 in order to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, and Avandaryl). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2016 Category: Drugs & Pharmacology Source Type: news
Pioglitazone, Not Rosiglitazone, Again Tied to Bladder CancerPioglitazone, Not Rosiglitazone, Again Tied to Bladder Cancer
"Substantial and fairly consistent" evidence points to pioglitazone as associated with increased risk of bladder cancer, and this study strengthens and "confirms" that evidence, an expert says. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Diabetes drug linked to increased bladder cancer risk
Conclusion
It seems likely from this research that pioglitazone is linked to an increased risk of bladder cancer, although the overall chances of getting bladder cancer remain very low. While this type of research cannot prove that pioglitazone is the cause of the increased risk of bladder cancer, it is not easy to find a convincing alternative explanation for these results.
Previous research has already shown unexpectedly higher levels of bladder cancer among people taking pioglitazone, although other studies had found no such link. However, the size and the care with which this new study was carried out makes it convinc...
Source: NHS News Feed - March 31, 2016 Category: Consumer Health News Tags: Cancer Diabetes Medication Source Type: news
FDA Statement on Avandia TIDE Trial
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2016 Category: Drugs & Pharmacology Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere que se eliminen ciertas restricciones al recetar y dispensar medicamentos para la diabetes que contienen rosiglitazona
El 25 de noviembre, 2013, La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) ha determinado que datos recientes sobre medicamentos que contienen rosiglitazona, como Avandia, Avandamet, Avandaryl y versiones genéricas, no indican un riesgo mayor de ataque al corazón en comparación con los medicamentos estándar metformina y sulfonilurea para la diabetes de tipo 2. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news
REMS No Longer Necessary for Rosiglitazone-Containing Diabetes Drugs (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
The Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 17, 2015 Category: Primary Care Source Type: news
FDA Lifts Final Regulatory Restrictions on RosiglitazoneFDA Lifts Final Regulatory Restrictions on Rosiglitazone
The FDA pulls the plug on its prior risk evaluation and mitigation strategy for rosiglitazone-containing type 2 diabetes medicines. News Alerts (Source: theHeart.org)
Source: theHeart.org - December 16, 2015 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Lifts Restriction On Rosiglitazone
(MedPage Today) -- Agency sees no need for restrictions after easing them 2 years ago (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 16, 2015 Category: Cardiology Source Type: news
